Bayesian Reanalysis of Revascularization Strategies for Left Main Disease: Coronary Artery Bypass Grafting vs Percutaneous Intervention.

Ann Thorac SurgMay 26, 2026 (epub)
Clinical ResearchCardiology

Zhenyu Li, Johan Larson, Dominique Vervoort et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis reexamines revascularization strategies for left main disease, comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The study found that CABG has over an 80% probability of being associated with lower all-cause mortality. Bayesian analysis indicated a hazard ratio of 1.1 for CABG under a minimally informative prior.

Key findings

  • CABG showed over 80% probability of lower all-cause mortality compared to PCI.
  • Under a downweighted historical prior, CABG had a hazard ratio of 1.40 for mortality.
  • CABG was associated with reduced rates of myocardial infarction and repeated revascularization.
  • PCI was associated with a lower risk of stroke, with a hazard ratio of 0.83.

Why it matters

Understanding the comparative effectiveness of CABG versus PCI for left main disease is crucial for guiding treatment decisions, particularly regarding long-term outcomes like mortality and myocardial infarction.

Source

PubMed · PMID 42203135

Published in Ann Thorac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.